TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07529808: Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Sponsor: BigHat Biosciences, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 164 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07529808 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07529808 Rescue Dossier →